secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outset Medical, Inc. (OM)
CIK:        0001484612
Form:       8-K
Filed at:   2022-02-16T23:59:59+00:00
Accession:  0000950170-22-001362
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outset Medical Q4 revenue $28.2M, FY21 $102.6M (+105%); guides FY22 $142-150M; CEO adds Chair
--------------------------------------------------------------------------------

- Q4 revenue $28.2M (+63% YoY); FY21 revenue $102.6M (+105.5% YoY). GAAP EPS ($0.87); non-GAAP EPS ($0.77).
- FY21 GAAP net loss $131.9M ($2.89/share); non-GAAP net loss $114.5M ($2.51/share).
- Q4 gross margin 11.8% (vs 2.4% YoY); cash and investments $372.8M at Dec 31, 2021.
- FY2022 revenue guidance $142M-$150M representing 38%-46% growth over FY2021.
- CEO Leslie Trigg appointed Chair of Board; D. Keith Grossman becomes Lead Independent Director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484612/000095017022001362/0000950170-22-001362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484612/000095017022001362/om-20220216.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-001362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer